<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149174</url>
  </required_header>
  <id_info>
    <org_study_id>EMDA/PRE-TUR/691836</org_study_id>
    <nct_id>NCT01149174</nct_id>
  </id_info>
  <brief_title>Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer</brief_title>
  <acronym>EMDA/PRE-TUR</acronym>
  <official_title>Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early single instillation of chemotherapy after TUR is recommended in the European
      Association of Urology Guidelines. Nevertheless, the procedure is suboptimal for patients
      with multiple tumors, sometimes is not tolerated and it can results in severe complications.
      In both laboratory and clinical studies, intravesical electromotive drug administration
      (EMDA) increases mitomycin-C (MMC) bladder uptake, resulting in an improved clinical efficacy
      in non-muscle invasive bladder cancer (NMIBC). The investigators will compare the effects of
      one immediate pre-TUR intravesical EMDA/MMC instillation with one immediate post-TUR
      intravesical passive diffusion MMC (PD/MMC) instillation and TUR alone in patients with
      NMIBC.

      All eligible patients with primary NMIBC will be randomized into 3 groups who will undergo
      transurethral resection alone (TUR/alone); TUR plus single immediate postoperative
      instillation (immediately after TUR) of 40 mg PD/MMC with a dwell time of 60 minutes; or
      single immediate preoperative instillation (immediately before TUR) of 40 mg EMDA/MMC with 20
      mA electric current for 30 minutes. Patients with intermediate and high risk NMIBC will
      undergo adjuvant intravesical therapy. The primary end points will be the recurrence rate and
      disease-free interval. All clinical analyses will be performed on an intent to treat basis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free interval and recurrence rate</measure>
    <time_frame>recurrence assessed at 1 and 3 years from randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease progression and overall and specific disease mortality</measure>
    <time_frame>progression and mortality assessed at 5 years from randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Superficial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>transurethral resection alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravesical mitomycin-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>electromotive mitomycin-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C 40 mg</intervention_name>
    <description>Intravesical instillation of Mitomycin-C</description>
    <arm_group_label>intravesical mitomycin-C</arm_group_label>
    <arm_group_label>electromotive mitomycin-C</arm_group_label>
    <other_name>Mytomicin-C Kyowa Italiana Farmaceutici Milano</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with primary histologically proven stage pTa-pT1 transitional-cell
             carcinoma of the bladder

        Exclusion Criteria:

          -  Previous treatments with bacillus Calmette-Guerin, mitomycin-C, or with any other
             intravesical cytostatic agent

          -  Concomitant urothelial tumours of the upper urinary tract

          -  Previous or concomitant muscle-invasive (ie, stage T2 or higher) transitional-cell
             carcinoma of the bladder

          -  Bladder capacity less than 200 ml

          -  Untreated urinary-tract infection

          -  Disease of upper urinary tract

          -  Previous radiotherapy to the pelvis

          -  Other concurrent chemotherapy

          -  Treatment with radiotherapy-response or biological-response modifiers

          -  Other malignant diseases within 5 years of trial registration (except for basal-cell
             carcinoma)

          -  Pregnancy or nursing

          -  And psychological, familial or sociological factors that would preclude study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Savino M Di Stasi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Tor Vergata&quot; University, Rome, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Surgery, Tor Vergata University</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting</url>
    <description>2010 ASCO Annual Meeting.</description>
  </link>
  <results_reference>
    <citation>Di Stasi SM, Verri C, Capelli G, Brausi M , Leprini G, Casilio M, Zampa G. Single preoperative intravesical instillation of electromotive mitomycin-C for primary non- muscle-invasive bladder cancer: A prospective randomized trial. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings. Vol 28, No 15 Suppl (May 20 Supplement), 2010: Abs # 4543.</citation>
  </results_reference>
  <results_reference>
    <citation>Di Stasi SM, Verri C, Capelli G, Brausi M, Leprini G, G Zampa, Stephen RL. Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle invasive bladder cancer: A randomized trial. The Journal of Urology, 2010 AUA Annual Meeting Proceedings. Vol 183, No. 4 Suppl (April Supplement), 2010: Abs #1346.</citation>
  </results_reference>
  <results_reference>
    <citation>Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, Masedu F, Ricci AR, Micali F, Vespasiani G. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011 Sep;12(9):871-9. doi: 10.1016/S1470-2045(11)70190-5. Epub 2011 Aug 8.</citation>
    <PMID>21831711</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>October 3, 2011</last_update_submitted>
  <last_update_submitted_qc>October 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Savino M. Di Stasi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>intravesical chemotherapy</keyword>
  <keyword>early single instillation</keyword>
  <keyword>mitomycin-C</keyword>
  <keyword>electromotive drug administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

